[QTc-interval prolongation in therapy with atypical antipsychotics--results of an open, non-randomized survey].
The introduction of Ziprasidone stimulated discussion about frequency and importance of QTc-interval prolongations with antipsychotic therapy. In an open non-randomized study we collected data about QTc-interval, electrolytes, vital parameters and associated clinical symptoms in patients treated with atypical antipsychotics. 33 patients were scanned and some moderate QTc-interval prolongations but no clinical events were seen. Due to scarcity of such events existing data should be completed by large scale clinical studies and by registration of severe QTc-interval prolongations and torsades de pointes in central drug monitoring systems.
Finzel
Martin
M
Bezirksklinikum Gabersee. martin.finzel@epost.de
Fric
Mirijam
M
Laux
Gerd
G
D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D004562:Electrocardiography / Q000187:drug effects; D005858:Germany; D006760:Hospitalization; D006778:Hospitals, Psychiatric; D006801:Humans; D008133:Long QT Syndrome / Q000139:chemically induced* / Q000175:diagnosis; D010879:Piperazines / Q000009:adverse effects* / Q000627:therapeutic use; D011446:Prospective Studies; D011618:Psychotic Disorders / Q000188:drug therapy*; D018570:Risk Assessment; D013844:Thiazoles / Q000009:adverse effects* / Q000627:therapeutic use; D016171:Torsades de Pointes / Q000139:chemically induced / Q000175:diagnosis
D014150:Antipsychotic Agents; D010879:Piperazines; D013844:Thiazoles; C092292:ziprasidone